Inserm Transfert Initiative (ITI) was created under the initiative of Inserm, the French National Institute of Health and Medical Research. Inserm is a biomedical and public health research institution with nearly 15,000 researchers, engineers, technicians and post-doctoral students as well as over 300 laboratories. It is the number one academic and clinical research organisation dedicated to human health in Europe.
In 2005, Inserm give Inserm Transfert — the Inserm private subsidiary for scientific tech-transfer — responsibility to establish a new fund, ITI, with the aim of creating a complete ecosystem around academic research institutions and addressing the need to finance early-stage life sciences companies. Together with Inserm Transfert, 3 investment funds - BPI France, Sofinnova Partners and Ventech - supported ITI’s inception.
In 2011, ITI raised €35.5 million from Inserm Transfert, BPI France (through the “Fonds National d’Amorçage”) and 10 pharmaceutical companies, making it one of the largest French life sciences seed investment funds.
Since September 2017, Inserm Transfert Initiative is managed by Sofimac Innovation.
ITI has developed a strong ecosystem of close partners, including:
These strong connections with public and private partners will facilitate finding, seeding and growing our portfolio companies.
![]() AAV-based gene therapy for genetic diseases including Friedreich’s Ataxia (cardiomyopathy) |
![]() Cannabinoid receptor antagonist therapies for central nervous system disorders |
![]() Robotized systems for Transcranial Magnetic Stimulation (TMS) |
![]() Super-resolution modules for optical microscopes |
![]() Modulation of DNA repair to sensitize tumors to chemo- and radio-therapy |
![]() Monoclonal antibody acting on co-stimulation of T cells for autoimmunity and transplantation |
![]() Treatments targeting intracellular targets to control viral replication |
![]() Non-viral gene therapy for ocular diseases |
![]() Genomic services |
![]() Development of oxygen-carriers from a marine organism |
![]() New drug targets for the treatment of Inflammatory Bowel Disease |
![]() Therapies for acute inflammatory processes in critical care setting |
![]() Monoclonal antibodies for cancer |
![]() Small molecule for inner ear disorders (vestibular and/or cochlear disorders) |
![]() Detection and analysis of circulating tumor cells |
![]() Second generation vaccines to prevent meningitis |
![]() New class of inhibitors for the treatment of autoimmune diseases |
![]() Treatment for rare forms of dwarfism such as achondroplasia |
![]() Vaccines based on an improved peptide technology focusing on cancer indications |
Inserm Transfert Initiative (ITI) raised €35,5 million in 2011 and was supported by public and private organizations as well as pharmaceutical companies. In 2005, investment funds also participated in ITI’s inception alongside Inserm Transfert.
c/o SOFIMAC Innovation
41 rue Boissy d'Anglas
75008 PARIS
France
Tel : +33 1 45 01 46 46
Direction: